Why Is Zydus Lifesciences Share Price Falling? Key Reasons And Share Price Target

Thu Apr 09 2026

Zydus Lifesciences is trading at Rs 860, down -20% from its 52-week high of Rs 1,300. The sustained decline in the Zydus Lifesciences share price reflects a combination of company-specific headwinds, sector pressures, and the broader macro overhang from the US 26% reciprocal tariff on Indian goods announced on April 2, 2026. This article explains every key reason behind the Zydus Lifesciences share price falling and provides a structured share price target for 2026.

Table of Contents

About Zydus Lifesciences

Click Here – Get Free Investment Predictions

Zydus Lifesciences (NSE: ZYDUSLIFE) is a leading listed company in the Pharma sector with a market capitalisation of Rs 86,000 Cr. The stock trades at approximately 26x P/E and 4.8x price-to-book. Its 52-week range is Rs 820 to Rs 1,300, and the current price of Rs 860 sits near the lower end of that range.

Why Is Zydus Lifesciences Share Price Falling? Key Reasons

Tap to Access Best Research Pieces on Univest

1. US Generics Pricing Pressure Intensifying

The US generics market has seen accelerated pricing pressure from consolidated generic drug purchasers (Walgreens Boots Alliance, CVS Health, and Rite Aid successors) who negotiate harder with every annual contract renewal. Zydus Lifesciences earns approximately 38% of its consolidated revenue from the US market. Price erosion of 4-6% per year on the base US business — net of new product launches — compresses the revenue growth trajectory even when volumes are healthy.

2. Asacol HD Exclusivity Cliff

Zydus had been earning meaningful exclusive revenue from mesalamine (Asacol HD 800mg), a drug used in ulcerative colitis, under a First-to-File patent settlement. This exclusivity period is ending, and multiple generics are entering the market. The revenue impact is estimated at Rs 400-500 crore on an annualised basis — a meaningful hole in Zydus’s US revenue mix that Q4 FY26 results will begin to reflect.

3. Insulin Aspart Approval Timeline Uncertainty

Zydus’s biosimilar insulin aspart (ZyTUS-B) in the US represents a significant long-term opportunity but faces a longer-than-expected FDA approval timeline. The US insulin biosimilar market is large — the branded market is over $4 billion — but regulatory pathways for biosimilars are complex and subject to delay. Any pushback in approval extends the period during which investors are waiting for this catalyst.

4. High-Value Product Cliff Post Key Exclusivities

The transition from high-margin first-wave exclusivity products to the base generics business involves a revenue mix deterioration that compresses overall EBITDA margins. Zydus’s EBITDA margin declined from 27.1% to 25.4% in Q3 FY26, and Q4 FY26 guidance suggests further compression to approximately 24-25% as the exclusivity cliff bites.

5. Premium Valuation vs. Indian Pharma Peers

At 26x P/E, Zydus commands a significant premium over most large-cap Indian generic pharma peers. This premium was justified by high-value US exclusivities and the growth trajectory of its specialty and biologics pipeline. As exclusivities wind down and the specialty pipeline faces delays, the premium is difficult to sustain at the same level.

Zydus Lifesciences Latest News That Impacted the Stock

Q3 FY26 results (February 2026): Revenue Rs 5,142 crore (+12% YoY), PAT Rs 894 crore. US business grew 18% CC — strong, but guidance cautious for Q4.

February 2026: Asacol HD (mesalamine) exclusivity period ending — generics competition enters. Revenue impact Rs 400-500 crore annualised.

March 2026: Biosimilar saroglitazar launch in the US faces delayed FDA approval — timeline pushed to H1 FY27.

April 2026: US pharma sector FII outflow. Generics pricing pressure macro continues.

Financial Performance Analysis

Zydus Lifesciences’s quarterly numbers provide important context for the share price decline. The table below highlights key metrics versus the year-ago quarter.

Key Metric	Latest Quarter	Year-Ago Quarter	YoY Change
Revenue	Rs 5,142 Cr	Rs 4,590 Cr	+12.0%
Net Profit	Rs 894 Cr	Rs 896 Cr	-0.2%
EBITDA Margin	25.4%	27.1%	-170 bps
US Business Rev	Rs 1,980 Cr	Rs 1,678 Cr	+18.0%

If you want to track Zydus Lifesciences’s financial metrics in real time, check the Univest Screener

Technical Signals: What the Charts Are Saying

Zydus is trading at Rs 860, near its 52-week low of Rs 820. Support at Rs 800-820. Resistance at Rs 980-1,050. RSI at 38 is approaching oversold but no technical reversal signal yet.

Download the Univest iOS App or Univest Android App to track Zydus Lifesciences’s live price.

Market Sentiment & Institutional Positioning

Promoter (Pankaj Patel family) holds 74.9% — stable and high conviction. FII holding at 16.2% — moderate and stable. DII at 9.8%. The stock lacks a major institutional catalyst to drive recovery without a product pipeline trigger.

Future Outlook: Can Zydus Lifesciences Recover?

Zydus’s recovery is a product pipeline story. Insulin aspart approval in the US would be a major positive catalyst. The India business — growing at 12-14% — provides a steady earnings floor. The innovative biologics portfolio (pegfilgrastim, adalimumab biosimilars) is globally positioned. The contrarian view: the market has not fully priced the 5-6 year pipeline of specialty and biologics launches, and at Rs 860, patient long-term investors are getting a meaningful discount to the intrinsic value of the pipeline.

Zydus Lifesciences Share Price Target

Subscribe to Univest Pro for Premium Stock Research and F&O Setups

Short-Term Target (3–6 Months)

Support and short-term range: Rs 820-900. The stock may remain in this band while near-term headwinds persist.

12-Month Analyst Target

The 12-month analyst consensus for Zydus Lifesciences is Rs 1,050-1,200, implying meaningful recovery potential from Rs 860.

Long-Term Target (2027–2028)

In a recovery scenario, the FY28 long-term target is Rs 1,400-1,600. Track live on Univest Screener.

Conclusion

Zydus Lifesciences share price falling -20% from Rs 1,300 reflects sector headwinds and stock-specific pressures. The 12-month analyst consensus of Rs 1,050-1,200 implies recovery potential. Short-term support is Rs 820-900. For more analysis, visit

Univest Blogs

Disclaimer: This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.

FAQs

Q1. Why is Zydus Lifesciences share price falling?

Zydus shares are falling due to the Asacol HD exclusivity period ending (Rs 400-500 crore revenue impact), US generics price erosion of 4-6% per year, insulin aspart FDA approval timeline uncertainty, EBITDA margin compression from 27.1% to 25.4%, and premium P/E valuation facing pressure as exclusivities wind down.

Q2. What is the Zydus share price target for 2026?

The 12-month analyst consensus is Rs 1,050-1,200. MOFSL targets Rs 1,150, YES Securities targets Rs 1,200. Short-term support is Rs 800-820.

Q3. What is Zydus’s insulin aspart biosimilar?

Zydus’s insulin aspart biosimilar (ZyTUS-B) is a recombinant human insulin analogue being developed for the US market. The US insulin biosimilar market is over $4 billion, and approval would be a meaningful revenue catalyst for Zydus’s long-term specialty pipeline.

Q4. What is Zydus’s US business revenue contribution?

US business contributes approximately 38% of Zydus Lifesciences’ consolidated revenue, approximately Rs 7,500-8,000 crore annualised. It is the highest-margin segment and the key driver of overall EBITDA margin.

Q5. What is Zydus’s promoter holding?

Promoter (Pankaj Patel family) holds 74.9% of Zydus Lifesciences — a high and stable stake.

Q6. What is Zydus’s EBITDA margin?

Zydus reported EBITDA margin of 25.4% in Q3 FY26, declining from 27.1% a year ago. The compression reflects the exclusivity cliff and product mix dilution.

Q7. What could trigger a Zydus share price recovery?

FDA approval of insulin aspart biosimilar, new US product launches filling the exclusivity gap, and India specialty branded business growing above 15% are the three primary recovery catalysts.

Q8. Is Zydus a good long-term investment?

Zydus has a strong track record, high promoter ownership, and a meaningful biosimilar pipeline. At Rs 860, it is near its one-year support. Long-term investors with 2-3 year horizon may find value, but near-term earnings visibility is limited. Consult a SEBI-registered advisor.